IntoCell, Inc.
6Patents
6Active
6Granted
48Portfolio score
Filing activity: Dec 28, 2017 → Jun 30, 2021
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US11065343B2 | Compound bearing beta-galactoside-introduced self-immolative linker | Emerging Cross-Sectional Technologies | 2 | Active |
| US11807628B2 | Benzodiazepine derivatives and uses thereof | Chemistry; Metallurgy | 1 | Active |
| US11084801B2 | Benzodiazepine derivatives and uses thereof | Chemistry; Metallurgy | 1 | Active |
| US12168060B2 | Antibody-drug conjugates comprising anti-B7-H3 antibodies | Chemistry; Metallurgy | 0 | Active |
| US11753431B2 | Compounds comprising cleavable linker and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US12274898B2 | Substituted benzodiazepines as antibody-drug conjugates | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.